Solidarity is an international clinical trial to evaluate the effect of a number of drugs for the treatment of COVID-19
The trial results indicate that treatment regimens with remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon appear to have little or no effect on 28-day mortality or hospital outcome in COVID-19 patients.
Description of the Study:
- Title: Solidarity.
- Principal Investigators: WHO Solidarity Trial Consortium, Hongchao Pan, Richard Peto, Quarraisha Abdool Karim, Marissa Alejandria, Ana Maria Henao-Restrepo, César Hernández García, Marie Paule Kieny, Reza Malekzadeh, Srinivas Murthy, Marie-Pierre Preziosi, Srinath Reddy, Mirta Roses Periago, Vasee Sathiyamoorthy, John-Arne Røttingen and Soumya Swaminathan.
- Countries of Implementation: The trial has been conducted in 30 of the 43 countries that are authorised to begin pre-screening participants. In total, 116 countries in all six WHO regions have joined the trial or expressed interest in participating.
- Study Population: As of 2 October 2020, more than 12,000 patients were enrolled in 500 participating hospitals worldwide. Patients are required to have COVID-19, be hospitalised, have agreed to participate in the trial, and meet the trial inclusion and exclusion criteria.
- Study Type: Randomised clinical trial.
- Design: Patients were randomly assigned equally to one of the trial drug regimens and the open control, so that there were up to five treatment options: four active and the local standard of care.
- Methods: The ITT (intention-to-treat) primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available and patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry.
Objectives of the Study:
Principal Objective: To assess the effect of drugs on three important outcomes in COVID-19 patients: mortality, need for ventilator support and duration of hospitalisation.
More about this Study:
Scientific Context: The new disease caused by a new coronavirus was first described in 2019 in China and is designated COVID-19 or COVID and the pathogen (an RNA virus) is designated SARS-coronavirus-2 (SARS-CoV-2). As of early 2020, there were no approved antiviral treatments available for COVID-19, so the WHO expert group recommended evaluating four existing treatments, Remdesivir, Lopinavir (given with Ritonavir, to alleviate liver degradation), Interferon Beta1a and Chloroquine or Hydrocholroquine through an international randomised trial to provide evidence-based data on them.
Added Value: This is one of the largest international randomised trials of COVID-19 treatments, involving nearly 12,000 patients in 500 hospitals in more than 30 countries.
Other Studies about Pharmacology:
This study conducted by the UOC aims to find out the opinion of the Spanish population and professional healthcare personnel on the COVID-19 vaccines.
Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).
MOOD-COVID aims to study the impact of the pandemic on the mental health of pregnant women, young mothers and their children.
This study aims to analyse the emotional and spiritual state of adults who have lost a loved one due to COVID-19.
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
This study proposal aims to determine whether early corticosteroid treatment can reduce the need for oxygen therapy and post-COVID sequelae.
This study aims to assess the mental health impact and needs associated with COVID-19 in Spain.
CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.
The NAUTILUS project aims to develop an artificial intelligence platform to identify, predict and intervene on persistent symptoms in people who have suffered from COVID-19.